Viridian Therapeutics, Inc.\DE (VRDN) Retained Earnings (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Retained Earnings history runs 14 years deep, the most recent figure standing at $1.9 billion for Q1 2026.

• On a quarterly basis, Retained Earnings rose 279.8% year-over-year to $1.9 billion in Q1 2026; TTM through Mar 2026 was $1.9 billion, a 279.8% increase from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 19271140.0% from the prior year.
• Retained Earnings improved to $1.9 billion in Q1 2026 per VRDN's latest filing, from $1.9 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $1.9 billion in Q1 2026 and bottomed at -$1.2 billion in Q3 2025.
• The 5-year median for Retained Earnings is -$442.4 million (2022), against an average of -$122.1 million.
• Across the five-year window, Retained Earnings slumped 310838.85% in 2022 and surged 19271140.0% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$488.2 million in 2022, then surged by 100.07% to $338000.0 in 2023, then plunged by 102.96% to -$10000.0 in 2024, then jumped by 19271140.0% to $1.9 billion in 2025, then increased by 1.02% to $1.9 billion in 2026.
• Per Business Quant, the three latest VRDN Retained Earnings figures stand at $1.9 billion (Q1 2026), $1.9 billion (Q4 2025), and -$1.2 billion (Q3 2025).